melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.
|
20925915 |
2010 |
melanoma
|
|
0.780 |
GeneticVariation
|
CLINVAR |
We generated mutant BRAF(V600E) melanoma cells that exhibit resistance to PLX4720, the tool compound for vemurafenib, that co-expressed mutant (Q61K) NRAS.
|
23076151 |
2012 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
In summary, this report indicates that N-RAS(Q61K) and B-RAF(V600E) contribute to melanoma's resistance to apoptosis in part by downregulating Bim expression, suggesting that Bim is a possible treatment target for overriding melanoma's inherent defenses against cell death.
|
18668139 |
2009 |
melanoma
|
|
0.780 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
We observed an increase in NRAS mutant allele percentage (NRAS-MA%) in the metastatic melanoma progression from 2 patients with melanomas harbouring a NRAS mutation (p.Q61K in case 1 and p.Q61R in case 2).
|
26990546 |
2016 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
Strikingly, the administration of BI-69A11 inhibited melanoma development in genetically modified mice bearing an inducible form of activated Nras and a deletion of the Ink4a gene (Nras((Q61K)) ::Ink4a(-/-) ).
|
23035722 |
2013 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
Molecular genetic analysis, including DNA sequencing and CGH, revealed that both areas contained an identical NRAS Q61K mutation and had highly similar CGH profiles, including gains of chromosome 1q and losses of 1p, 4, 9, and 10, which are archetypical of melanoma.
|
21836492 |
2011 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
Here, using a bigenic mouse model system combining mutant oncogenic NRAS(Q61K) (constitutively active RAS) or mutant activated CDK4(R24C/R24C) (prevents binding of CDK4 by kinase inhibitor p16(INK4A)) with an epidermis-specific knockout of the nuclear retinoid X receptor alpha (RXRα(ep-/-)) results in increased melanoma formation after chronic ultraviolet-B (UVB) irradiation compared with control mice with functional RXRα.
|
25189354 |
2015 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
Nine cases presented concomitant BRAF and NRAS mutations, including one case in which both the melanoma and the adjacent naevus harboured V600E and Q61K double mutations.
|
25857817 |
2015 |
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
In this study, we performed an integrative analysis of DNA methylation, gene expression, and microRNA expression data to identify potential regulatory pathways associated with the most common driver mutations in NRAS (Q61K/L/R) through comparison of NRASQ61-mutated melanomas with pan-negative melanomas.
|
25537510 |
2015 |
GIANT PIGMENTED HAIRY NEVUS
|
|
0.700 |
GeneticVariation
|
UNIPROT |
Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.
|
23392294 |
2013 |
GIANT PIGMENTED HAIRY NEVUS
|
|
0.700 |
GeneticVariation
|
UNIPROT |
Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis.
|
18633438 |
2009 |
Neurocutaneous melanosis
|
|
0.700 |
GeneticVariation
|
UNIPROT |
Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.
|
23392294 |
2013 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.030 |
GeneticVariation
|
BEFREE |
We report two cases of mCRC with a Q61K NRAS mutation that had a favorable response to bevacizumab and the histone deacetylase inhibitor valproic acid.
|
23400451 |
2013 |
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
Molecular investigations were performed post-mortem on tumor tissue and revealed absence of BRAF(V600E), GNAQ(Q209) and GNA11(Q209) mutations but the presence of a NRAS(Q61K) mutation.
|
27439913 |
2016 |
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
However, in human non-small-cell lung carcinoma H1299 cells harboring N-Ras Q61K oncogenic mutation and p53 deletion, overexpression of Nm23H1 did not affect tumorigenesis in nude mice assays, while overexpression of Nm23H2 enhanced tumor growth with elevated expression of the c-Myc proto-oncogene.
|
25748386 |
2015 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.030 |
GeneticVariation
|
BEFREE |
Using a system of paired NRAS-mutant and wild-type isogenic mCRC cell lines to explore signaling pathways engaged by the common oncogenic NRAS Q61K variant upon challenge with cetuximab, we uncovered an unexpected mechanism of resistance to cetuximab involving dysregulation of the ephrin-A1/EphA2 signaling axis.
|
28560458 |
2017 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.030 |
GeneticVariation
|
BEFREE |
Using isogenic mCRC cells with a heterozygous knock-in of the NRAS activating mutation Q61K, we aimed to elucidate the mechanism(s) by which mutant NRAS blocks cetuximab from inhibiting mCRC growth.
|
27636997 |
2016 |
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
Other mutations included: 1/78 (1.3%) successfully amplified tumor samples with TERT<sup> C228T</sup>; 2/79 (2.5%) NRAS 61 (c.181C>A and c.182A>G); 1/73 (1.4%) PIK3CA exon 9 (c.1589A>G and c.1598C>T in one tumor); 1/79 (1.3%) PIK3CA exon 20 (c.2951G>A); and 1/74 (1.4%) PTEN exon 5 (c.295G>A).
|
27824297 |
2017 |
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
We identified two NRAS-activating somatic mutations, Q61R and Q61K, affecting two main subpopulations in the metastasis PV1 and a BRAF alternative splicing, involving exons 4-10, in the metastasis PV2.
|
23948972 |
2013 |
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
The absence of PTEN leads to caveolin-1 (CAV1)-dependent β-catenin transcriptional modulation in vitro, cooperates with NRAS(Q61K) to initiate melanomagenesis in vivo and induces efficient metastasis formation associated with E-cadherin internalization.
|
26307673 |
2015 |
Congenital naevus
|
|
0.010 |
GeneticVariation
|
BEFREE |
A mutation in the Cdon gene potentiates congenital nevus development mediated by NRAS(Q61K).
|
27155367 |
2016 |
Metastatic melanoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We observed an increase in NRAS mutant allele percentage (NRAS-MA%) in the metastatic melanoma progression from 2 patients with melanomas harbouring a NRAS mutation (p.Q61K in case 1 and p.Q61R in case 2).
|
26990546 |
2016 |
Sebaceous adenoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A KRAS mutation G12C (c.34G>T, p.Gly12Cys) was detected in 1 sebaceous adenoma and a NRAS mutation Q61K (c.181C>A, p.Gln61Lys) was found in 2 other sebaceous adenomas.
|
27870730 |
2016 |
Adult Diffuse Large B-Cell Lymphoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).
|
22575864 |
2012 |